Multivir Inc. Receives Patent for Innovative Cancer Therapy Methods

Multivir Inc.'s team of innovative researchers has made groundbreaking strides in cancer treatment with the approval of a patent for their pioneering methods and compositions utilizing tumor suppressor gene therapy and CD122/CD132 agonists for cancer treatment. This achievement has shed new light on the possibility of eradicating cancer through targeted therapies. The innovative methods have shown exceptional results in treating aggressive forms of cancer, leading to complete tumor remissions and curative outcomes in previously resistant cases.

Key Takeaways:

• The patent (No. US 12454561 B2) was developed by four inventors: Robert E. Sobol, Kerstin B. Menander, Dora Wiederhold, and Sunil Chada for Methods and compositions comprising tumor suppressor gene therapy and CD122/CD132 agonists for the treatment of cancer.
• The methods and compositions described in the patent involve administering effective amounts of CD 122/CD 132 agonists, immune checkpoint inhibitors, and viral compositions engineered to overexpress a tumor suppressor gene and/or an adenoviral death protein.
• The treatments also include combinations of oncolytic viral compositions, CD122/CD132 agonists, and immune checkpoint inhibitors designed to enhance anti-tumor efficacy.
• Notably, these methods have led to complete tumor remissions and curative outcomes in highly aggressive forms of cancer that were previously resistant to immune therapies.

Statistics:

• The patent was initially filed on March 19, 2019.
• The patent's approval provides a significant milestone for cancer research with a focus on targeted therapies.
• The treatments described in the patent were tested on aggressive forms of cancer, resulting in exceptional outcomes, including complete tumor remissions and curative outcomes.

Sources:

• US Patent 12454561 B2, filed on March 19, 2019